Scott Wright  美国明尼苏达州罗彻斯特医院

    <International Circulation>:  Regarding clopidogrel， prasugrel， and ticagrelor， in the new guidelines you put in prasugrel as a first line treatment for ACS but ticagrelor is not in there.  Why is that?

  《国际循环》： 关于氯吡格雷，普拉格雷和替卡格雷，您在新的指南里把普拉格雷作为ACS治疗的一线用药，但是替卡格雷却不在其中，这是为什么呢？
 
    Prof. Wright:  That is correct.  It is not in there because of a specific rule in terms of righting guidelines， that is， if the drug is not FDA approved by the time the guidelines are being published than it cannot be included.  It is ok to say that we are working on a revision of the guidelines that will address the appropriate use of ticagrelor， which should come out next year.

    Wright教授:完全正确。它之所以不在其中是因为在指南的制订方面有一个特殊的规定，即如果该药物在指南公布的时候没有被FDA批准，它就不能被写入指南中。这其实没关系，我们正在修改指南，并将提出替卡格雷的适当用法，预计该指南将于明年公布。